CriticalPotassium salt with systemic alkalinising effect, used for kidney stone prevention and hypokalaemia×Potassium-sparing diuretic, collecting duct sodium channel blocker
Updated · Methodology
Mechanism
Triamterene inhibits the reabsorption of sodium in exchange for potassium and hydrogen ions in the distal tubule of the kidney and conserves potassium, sometimes to the point of hyperkalaemia (triamterene label, US Food and Drug Administration, FDA). It blocks sodium channels, so the kidneys excrete more sodium and less potassium (furosemide/triamterene summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Potassium citrate is a potassium salt: one 1080 mg tablet contains 10 mEq, or 390 mg, of potassium (potassium citrate SmPC, AEMPS). When the kidneys cannot excrete potassium properly, potassium citrate can cause hyperkalaemia and cardiac arrest, and with a potassium-sparing diuretic such as triamterene it can cause severe hyperkalaemia (potassium citrate label, FDA).
Symptoms
Hyperkalaemia is usually asymptomatic and may show only as a raised serum potassium and characteristic changes on the electrocardiogram (ECG): peaked T waves, loss of P waves, ST segment depression and QT prolongation. Late signs are muscle paralysis and cardiac arrest. Life-threatening hyperkalaemia can develop rapidly (potassium citrate label, US Food and Drug Administration, FDA). With any potassium-sparing agent, including triamterene, potassium can rise to 5.5 mEq/L or higher, more often in people with impaired kidney function or diabetes, in older people and in the severely ill. Uncorrected hyperkalaemia may be fatal, and rarely it has been associated with heart rhythm disturbances (triamterene label, FDA).
Management
The combination is contraindicated in the documents of both drugs. The US potassium citrate label contraindicates potassium citrate in patients receiving potassium-sparing agents and names triamterene. The Spanish summary of product characteristics (SmPC) says potassium citrate must not be given to patients receiving potassium-sparing diuretics and also names triamterene (potassium citrate label, US Food and Drug Administration, FDA, and potassium citrate SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US triamterene label says not to give dietary potassium supplements, potassium salts or potassium-containing salt substitutes with triamterene. When triamterene is added to other diuretics or a patient is switched to it, the label says to stop all potassium supplements (triamterene label, FDA). The Spanish furosemide/triamterene SmPC warns that triamterene with potassium salts increases the risk of both low and high potassium (AEMPS). During triamterene treatment, monitor serum potassium and blood urea nitrogen periodically, especially in older people and people with diabetes. Obtain an electrocardiogram (ECG) if hyperkalaemia is suspected, and stop triamterene and any potassium supplementation if hyperkalaemia is present (FDA). A widened QRS complex or arrhythmia requires prompt additional treatment (FDA). During potassium citrate treatment, monitor electrolytes, creatinine and the complete blood count every 4 months, more often in heart or kidney disease or acidosis. Perform periodic ECGs, and stop potassium citrate if hyperkalaemia develops (potassium citrate label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Furosemida/Triamtereno, Salidur 77,6 mg/25 mg (nº registro 53542), sección 4.5 (2024)– AEMPS, CIMA, nº registro 53542 (Salidur 77,6 mg/25 mg comprimidos, furosemida xantinol y triamtereno, Laboratorios Almirall), revisión 04/2024, secciones 4.3, 4.5 y 5.1
- FDA: Dyrenium (triamterene) capsules prescribing information (2024)– FDA, DailyMed setid ebb177c0-d45d-4443-a85a-e76bd9931a42 (Advanz Pharma US), versión 11, publicada 24/12/2024, Clinical Pharmacology, Contraindications, Warnings, Precautions (Laboratory Tests, Drug Interactions) y Dosage and Administration
- AEMPS: Ficha técnica: Citrato potásico, Acalka 1080 mg (nº registro 60014), sección 4.5 (2016)– AEMPS, CIMA, nº registro 60014 (Acalka 1080 mg comprimidos de liberación prolongada, Ferrer Internacional), revisión 06/2016, secciones 2, 4.3, 4.5, 4.8 y 4.9
- FDA: Urocit-K (potassium citrate) extended-release tablets prescribing information (2026)– FDA, DailyMed setid 72cdea1b-2240-41db-987d-86d5c6aaa978 (Mission Pharmacal), versión 30, publicada 23/07/2026, secciones 2.1, 4, 5.1, 7.1, 7.3, 10 y 12